Flavonoids from Pterogyne nitens Inhibit Hepatitis C Virus Entry

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Shimizu, Jacqueline Farinha ^a,b   Lima, Caroline Sprengel ^a   Pereira, Carina MacHado ^a   Bittar, Cintia ^a   Batista, Mariana Nogueira ^a   Nazaré, Ana Carolina ^a   Polaquini, Carlos Roberto ^a   Zothner, Carsten ^c   Harris, Mark ^c   Rahal, Paula ^a   Regasini, Luis Octávio ^a   Jardim, Ana Carolina Gomes ^a,b  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; FLAVONE DERIVATIVE; FLAVONOID; PEDALITIN;

CHEMISTRY; DRUG EFFECT; FABACEAE; HEPACIVIRUS; VIRUS REPLICATION;

ANTIVIRAL AGENTS; FABACEAE; FLAVONES; FLAVONOIDS; HEPACIVIRUS; INTERFERON-ALPHA; VIRUS REPLICATION;

EID: 85034849661     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-16336-y     Document Type: Article

References (61)

1. Choo, Q., Kuo, G., Weiner, A. & Overby, L. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science (80-.). 244, 359-362 (1989).
2. World Health Organisation. WHO | Hepatitis C. WHO (2016). Available at: http://www. who. int/mediacentre/factsheets/fs164/en/. (Accessed: 14th February 2017).
3. Simmonds, P. et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42, 962-973 (2005).
4. Rosen, H. R. Chronic Hepatitis C Infection. N. Engl. J. Med. 364, 2429-2438 (2011).
5. Gaetano, J. Benefit-risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir. Drug. Healthc. Patient Saf. 6, 37 (2014).
6. Mcquaid, T., Savini, C. & Seyedkazemi, S. Sofosbuvir, a Significant Paradigm Change in HCV Treatment. J. Clin. Transl. Hepatol. 3, 27-35 (2015).
7. Soriano, V., Peters, M. G. & Zeuzem, S. New Therapies for Hepatitis C Virus Infection. Clin. Infect. Dis. 48, 313-320 (2009).
8. Lawitz, E. et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect. Dis. 13, 401-408 (2013).
9. Barth, H. Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. World J. Hepatol. 7, 725 (2015).
10. Poveda, E. et al. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res. 108, 181-191 (2014).
11. Wyles, D. L. Antiviral Resistance and the Future Landscape of Hepatitis C Virus Infection Therapy. J. Infect. Dis. 207, S33-S39 (2013).
12. Brahmachari, G. in Bioactive Natural Products 1-199 https://doi. org/10. 1142/9789814335386-0001. (WORLD SCIENTIFIC, 2011).
13. Dixon, R. A., Dey, P. M. & Lamb, C. J. In (ed. Meister, A.) 1-136 (John Wiley & Sons, Inc., 2006). https://doi. org/10. 1002/978047012 3010. ch1.
14. Ho, H.-Y., Cheng, M.-L., Weng, S.-F., Leu, Y.-L. & Chiu, D. T.-Y. Antiviral Effect of Epigallocatechin Gallate on Enterovirus 71. J. Agric. Food Chem. 57, 6140-6147 (2009).
15. Weber, C., Sliva, K., von Rhein, C., Kümmerer, B. M. & Schnierle, B. S. The green tea catechin, epigallocatechin gallate inhibits chikungunya virus infection. Antiviral Res. 113, 1-3 (2015).
16. Calland, N. et al. (?)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology 55, 720-9 (2012).
17. Lyu, S.-Y., Rhim, J.-Y. & Park, W.-B. Antiherpetic activities of flavonoids against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in vitro. Arch. Pharm. Res. 28, 1293-1301 (2005).
18. Goldwasser, J. et al. Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. J. Hepatol. 55, 963-971 (2011).
19. Haid, S. et al. A Plant-Derived Flavonoid Inhibits Entry of All HCV Genotypes Into Human Hepatocytes. Gastroenterology 143, 213-222. e5 (2012).
20. Blaising, J. et al. Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking. Cell. Microbiol. 15, 1866-82 (2013).
21. Burkart, A. Las Leguminosas Argentinas. Buenos Aires Aemé Agency (1952).
22. Crivos, M. et al. Pathways as 'signatures in landscape': towards an ethnography of mobility among the Mbya-Guaraní (Northeastern Argentina). J. Ethnobiol. Ethnomed. 3, 2 (2007).
23. Satake, K. et al. Human ABCB1 confers cells resistance to cytotoxic guanidine alkaloids from Pterogyne nitens. Biomed. Mater. Eng. 25, 249-256 (2015).
24. REGASINI, L. O. et al. Identification of triterpenes and sterols from Pterogyne nitens (fabaceae-caesalpinioideae) using highresolution gas chromatography. J. Chil. Chem. Soc. 54, 218-221 (2009).
25. Regasini, L. O. et al. Free radical scavenging activity of Pterogyne nitens Tul. (Fabaceae). African J. Biotechnol. 7, 4609-4613 (2008).
26. Regasini, L. O. et al. Antiproliferative effect of Pterogyne nitens on melanoma cells. Rev. Ciencias Farm. Basica e Apl. 28, 335-340 (2007).
27. Regasini, L. O. et al. Flavonols from Pterogyne nitens and their evaluation as myeloperoxidase inhibitors. Phytochemistry 69, 1739-1744 (2008).
28. Fernandes, D. C. et al. Myeloperoxidase Inhibitory and Radical Scavenging Activities of Flavones from Pterogyne nitens. Chem. Pharm. Bull. (Tokyo). 56, 723-726 (2008).
29. Regasini, L. O. et al. Constituintes químicos das flores de Pterogyne nitens (Caesalpinioideae). Quim. Nova 31, 802-806 (2008).
30. Pasquini-Netto, H. et al. Avaliação das atividades antioxidante, anti e pró-hemolítica do extrato etanólico das folhas de pterogyne nitens Tul. (Fabaceae-Caesalpinioideae). Rev. Bras. Plantas Med. 14, 666-672 (2012).
31. Vellosa, J. C. R. et al. Antioxidant and cytotoxic studies for kaempferol, quercetin and isoquercitrin. Eclet. Quim. 36, 7-20 (2011).
32. Vellosa, J. C. R. et al. Preliminary in vitro and ex vivo evaluation of afzelin, kaempferitrin and pterogynoside action over free radicals and reactive oxygen species. Arch. Pharm. Res. 38, 1168-1177 (2015).
33. Lima, C. S. et al. Anti-Candida and anti-Cryptococcus evaluation of 15 non-alkaloidal compounds from Pterogyne nitens. Asian Pac. J. Trop. Biomed. 6, 841-845 (2016).
34. Bukh, J., Purcell, R. H. & Miller, R. H. At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. Proc. Natl. Acad. Sci. USA 90, 8234-8 (1993).
35. Shibata, C. et al. The flavonoid apigenin inhibits hepatitis C virus replication by decreasing mature microRNA122 levels. Virology 462-463, 42-8 (2014).
36. Lou, S. et al. Inhibition of Hepatitis C Virus Replication In Vitro by Xanthohumol, A Natural Product Present in Hops. Planta Med. 80, 171-176 (2013).
37. Nahmias, Y. et al. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology 47, 1437-1445 (2008).
38. Wyles, D. L. et al. The Octadecyloxyethyl Ester of (S)-9-[3-Hydroxy-2-(Phosphonomethoxy) Propyl]Adenine Is a Potent and Selective Inhibitor of Hepatitis C Virus Replication in Genotype 1A, 1B, and 2A Replicons. Antimicrob. Agents Chemother. 53, 2660-2662 (2009).
39. Calland, N. et al. Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action. J. Virol. 89, 10053-10063 (2015).
40. Souza, J., Molfetta, F. A., Honorio, K. M., Santos, R. H. A. & DaSilva, A. B. F. A Study on the Antipicornavirus Activity of Flavonoid Compounds (Flavones) by Using Quantum Chemical and Chemometric Methods. J. Chem. Inf. Model. 44, 1153-1161 (2004).
41. Erlejman, A. G., Verstraeten, S. V., Fraga, C. G. & Oteiza, P. I. The Interaction of Flavonoids with Membranes: Potential Determinant of Flavonoid Antioxidant Effects. Free Radic. Res. 38, 1311-1320 (2004).
42. Heim, K. E., Tagliaferro, A. R. & Bobilya, D. J. Flavonoid antioxidants: Chemistry, metabolism and structure-activity relationships. Journal of Nutritional Biochemistry 13, 572-584 (2002).
43. Kumar, S. & Pandey, A. K. Chemistry and biological activities of flavonoids: an overview. ScientificWorldJournal. 2013, 162750 (2013).
44. Chacko, K. R. & Gaglio, P. J. Meet the Classes of Directly Acting Antiviral Agents. Strengths and Weaknesses. Clin. Liver Dis. 19, 605-617 (2015).
45. Moradpour, D., Penin, F. & Rice, C. M. Replication of hepatitis C virus. Nat. Rev. Microbiol. 5, 453-463 (2007).
46. Jardim, A. C. G. et al. Analysis of HCV quasispecies dynamic under selective pressure of combined therapy. BMC Infect. Dis. 13, 61 (2013).
47. Nakamoto, S., Kanda, T., Wu, S., Shirasawa, H. & Yokosuka, O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J. Gastroenterol. 20, 2902-2912 (2014).
48. Ji, H. et al. Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations. Virology 477, 1-9 (2015).
49. Hajj, R. et al. Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease. Sci. Rep. 5, 16084 (2015).
50. Lin, C., Huang, Y., Cheng, L., Sheu, S. & Chen, C. Bioactive flavonoids from Ruellia tuberosa. J Chin Med 17, 103-109 (2006).
51. Zaidi, F., Voirin, B., Jay, M. & Viricel, M. R. Free flavonoid aglycones from leaves of mentha pulegium and mentha suaveolens (Labiatae). Phytochemistry 48, 991-994 (1998).
52. Agrawal, P. K., Bansal, M. C., Porter, L. J. & Foo, L. Y. In Studies in Inorganic Chemistry 39, 432-496 (1989).
53. Harborne, J. B. & Williams, C. A. Advances in flavonoid research since 1992. Phytochemistry 55, 481-504 (2000).
54. Test No. 117: Partition Coefficient (n-octanol/water), HPLC Method. (OECD Publishing, 2004). https://doi. org/10. 1787/9789264069824-en.
55. Ciesek, S. et al. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology 54, 1947-1955 (2011).
56. Watashi, K., Hijikata, M., Hosaka, M., Yamaji, M. & Shimotohno, K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38, 1282-8 (2003).
57. Ciesek, S. et al. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology 50, 1638-1645 (2009).
58. Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11, 791-6 (2005).
59. Gottwein, J. M. et al. Robust Hepatitis C Genotype 3a Cell Culture Releasing Adapted Intergenotypic 3a/2a (S52/JFH1) Viruses. Gastroenterology 133, 1614-1626 (2007).
60. Jardim, A. C. G. et al. Natural compounds isolated from Brazilian plants are potent inhibitors of hepatitis C virus replication in vitro. Antiviral Res. 115, 39-47 (2015).
61. Macdonald, A. et al. The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing Ras-ERK pathway signaling. J. Biol. Chem. 278, 17775-17784 (2003).